Page last updated: 2024-12-11
carpetimycin a
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
carpetimycin A: from Streptomyces sp. KC-6643; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 9578204 |
MeSH ID | M0097438 |
Synonyms (14)
Synonym |
---|
carpetimycin a |
(5r,6r)-3-[(r)-[(e)-2-acetamidoethenyl]sulfinyl]-6-(2-hydroxypropan-2-yl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid |
c 19393 h(2) |
76025-73-5 |
2lv1x0v38m , |
1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((2-(acetylamino)ethenyl)sulfinyl)-6-(1-hydroxy-1-methylethyl)-7-oxo-, (5r-(3(r*(e)),5alpha,6beta))- |
unii-2lv1x0v38m |
c-19393 h(2) |
carpetimycin a [mi] |
c-19393-h2 |
antibiotic ka-6643-a |
1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((r)-((1e)-2-(acetylamino)ethenyl)sulfinyl)-6-(1-hydroxy-1-methylethyl)-7-oxo-, (5r,6r)- |
antibiotic c-19393-h2 |
Q27254906 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (8)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 7 (87.50) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (12.50) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.09
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.09) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |